Appendix A

Claim Amendments

1. (Original) A dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor whose solubility is slight, comprising the PDE 4 inhibitor whose solubility is slight together with polyvinylpyrrolidone as binder, and one or more other suitable pharmaceutical excipients.

2. (Currently amended) The dosage form as claimed in claim 1, ~~where~~ wherein the one or more other suitable pharmaceutical excipients are ~~excipients~~ selected from the group consisting of fillers, binders, ~~and~~ lubricants, ~~or~~ release agents, and mixtures thereof.

3. (Currently amended) The dosage form as claimed in claim 1, which is a solid oral dosage form with immediate release of active ingredient ~~(immediate release solid oral dosage form)~~.

4. (Original) The dosage form as claimed in claim 1, which is a tablet.

5. (Original) The dosage form as claimed in claim 1, where the PDE 4 inhibitor whose solubility is slight is a compound having a solubility in water of less than or equal to 100 milligram/liter at a temperature of from 15 to 25°C.

6. (Currently amended) The dosage form as claimed in claim 1, where the PDE 4 inhibitor is a compound selected from the group of compounds of the formula I



(I)

in which either

R1 is 3-7C cycloalkoxy, 3-7C cycoalkylmethoxy or benzyloxy and

R2 is 1-4C alkoxy which is completely or partly substituted by fluorine,

or

R1 is 1-4C alkoxy which is completely or partly substituted by fluorine and

R2 is 3-7C cycoalkylmethoxy or benzyloxy,

and

R3 is phenyl, pyridyl, phenyl substituted by R31, R32 and R33, or pyridyl substituted by R34, R35, R36 and R37, where

R31 is hydroxyl, halogen, cyano, carboxyl, trifluoromethyl, 1-4C alkyl, 1-4C alkoxy, 1-4C alkoxycarbonyl, 1-4C alkylcarbonyl, 1-4C alkylcarbonyloxy, amino, mono- or di-1-4C alkylamino or 1-4C alkylcarbonylamino,

R32 is hydrogen, hydroxyl, halogen, amino, trifluoromethyl, 1-4C alkyl or 1-4C alkoxy,

R33 is hydrogen, halogen, 1-4C alkyl or 1-4C alkoxy,

R34 is hydroxyl, halogen, cyano, carboxyl, 1-4C alkyl, 1-4C alkoxy, 1-4C alkoxycarbonyl or amino,

R35 is hydrogen, halogen, amino or 1-4C alkyl,

R36 is hydrogen or halogen,

R37 is hydrogen or halogen,

~~the salts of these compounds and the N-oxides of the pyridines and the salts~~ or a salt of this compound, an

N-oxide of a pyridine of this compound, or a salt thereof.

7. (Currently amended) The dosage form as claimed in claim 6, which comprises a compound of the formula I in which

R1 is difluoromethoxy,

R2 is cyclopropylmethoxy and

R3 is 3,5-dichloropyrid-4-yl,

~~the salts of this compound, and the N-oxide of the pyridine and salts~~ or a salt of this compound, an N-oxide of a pyridine of this compound, or a salt thereof.

8. (Currently amended) A process for producing a dosage form as claimed in claim 1, comprising the steps:

(a) ~~production of~~ producing a mixture of a PDE 4 inhibitor and one or more pharmaceutical excipients and

(b) ~~granulation of~~ granulating the mixture obtained in (a) with an aqueous solution of PVP.

9. (Currently amended) A process for producing a dosage form as claimed in claim 1, comprising the steps:

(a) ~~production of~~ producing a mixture of one or more pharmaceutical excipients and

(b) ~~granulation of~~ granulating the mixture obtained in (a) with a suspension of ~~the active ingredient~~ a PDE 4 inhibitor in an aqueous solution of PVP.

10. (Currently amended) A process for producing a dosage form as claimed in claim 1, comprising ~~the production of~~ producing a solid solution of PVP and a PDE 4 inhibitor whose solubility is slight, comprising the following steps:

(a) dissolving PVP and a PDE 4 inhibitor whose solubility is slight in a suitable solvent, and

(b) removing the solvent from the solution of PVP and PDE 4 inhibitor.

11. (Canceled)

12. (New) The process according to claim 10, comprising producing a solid solution of PVP and a PDE 4 inhibitor whose solubility is slight, comprising the following steps:

(a) dissolving PVP, a PDE 4 inhibitor whose solubility is slight, and one or more pharmaceutical excipients in a suitable solvent, and

(b) removing the solvent from the solution of PVP and PDE 4 inhibitor.

13. (New) The process according to claim 10, wherein the solvent is removed by spray drying, normal drying, vacuum drying or freeze-drying.

14. (New) A process for producing a dosage form as claimed in claim 1, comprising producing a solid solution of PVP and PDE 4 inhibitor whose solubility is slight, comprising mixing a PDE 4 inhibitor whose solubility is slight with PVP.

15. (New) The process according to claim 14, comprising producing a solid solution of PVP and PDE 4 inhibitor whose solubility is slight, comprising mixing a PDE 4 inhibitor whose solubility is slight with PVP and one or more pharmaceutical excipients.

16. (New) A method of preventing or treating a disease or disorder in a patient treatable with a PDE 4 inhibitor, comprising administering to a patient in need thereof a therapeutically effective amount of a dosage form as claimed in claim 1.

17. (New) A method of preventing or treating an airway disorder in a patient treatable with a PDE 4 inhibitor, comprising administering to a patient in need thereof a therapeutically effective amount of a dosage form as claimed in claim 1.